SBT-6050
- Generic Name
- SBT-6050
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Phase 1
Terminated
- Conditions
- HER2-positive Gastric CancerHER2-positive Breast CancerHER2-expressing Non-small Cell Lung CancerHER2-positive Colorectal Cancer
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Silverback Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT05091528
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
Phase 1
- Conditions
- HER2 Positive Solid Tumors
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Silverback Therapeutics
- Target Recruit Count
- 58
- Registration Number
- NCT04460456
- Locations
- 🇺🇸
University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇦🇺Macquarie University Hospital Clinical Trials Unit, Sydney, New South Wales, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath